Type 2 Diabetes Mellitus (T2DM) remains a leading contributor to cardiovascular mortality worldwide. This study was conducted to investigate the pattern of circulating Endothelial Progenitor Cells (EPCs) in T2DM patients in comparison with MetS subjects.
Aim: To investigate the pattern of circulating EMPs in T2DM patients in comparison with MetS subjects.
Methods: The study retrospectively evolved 101 patients (54 subjects with T2DM and 47 patients with MetS) and 35 healthy volunteers. All the patients have given written informed consent for participation in the study. The flow cytometry was used for predictably distinguishing cell subsets, which depend on expression of CD45, CD34, CD14, Tie-2, and VEGFR2. Biomarkers were measured at baseline of the study.
Results: There is a significant difference between the medians of absolute numbers and frequencies of CD14+CD309+ and CD14+CD309+Tie2+ in healthy volunteers and patients with dysmetabolic disorders respectively. CD14+CD309+ and CD14+CD309+Tie2+ subsets of circulating EPCs were determined in higher concentration among MetS subjects in comparison with T2DM patients. Osteoprotegerin (OPG) and hs-C-Reactive Protein (CRP), improve significantly predictive model based on T2DM + number of Multiple Cardiovascular Risk Factors (MCRFs) >3 for decreased both angiopoetic phenotypes of circulating EPCs. Among patient study population for category-free NRI, 5% of events (p=0.001) and 11% of non-events (p=0.001) were correctly reclassified by the addition of hs-CRP and OPG to the base model for decreased absolute number of circulating EPCs labeled CD14+CD309+. Therefore, 6% of events (p=0.001) and 14% of non-events (p=0.002) were correctly reclassified using category-free NRI for depleted absolute number of circulating EPCs labeled CD14+CD309+Tie2+. In conclusion, we suggest that inflammatory biomarkers (hs-CRP, OPG) may consider statistically significant predictors for decreased EPCs labeled CD14+CD309+ and CD14+CD309+Tie2+ among dysmetabolic patients without preexisting atherosclerotic lesions of coronary arteries.